INSMED Inc. Files 8-K Report
Ticker: INSM · Form: 8-K · Filed: 2025-08-12T00:00:00.000Z
Sentiment: neutral
Topics: 8-K, financial-statements, sec-filing
Related Tickers: INSM
TL;DR
INSMED filed an 8-K, likely with financial updates. Keep an eye out for details.
AI Summary
On August 12, 2025, INSMED Incorporated filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates INSMED Inc. is providing updated information to the SEC, which could include material disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, with no immediate indication of significant negative events.
Key Players & Entities
- INSMED Inc. (company) — Registrant
- August 12, 2025 (date) — Date of Report
- Virginia (jurisdiction) — State of Incorporation
- 000-30739 (filing_id) — SEC File Number
- 54-1972729 (tax_id) — IRS Employer Identification No.
- 700 US Highway 202/206 (address) — Principal Executive Offices
- Bridgewater (city) — Principal Executive Offices
- New Jersey (state) — Principal Executive Offices
- 08807 (zip_code) — Principal Executive Offices
- (908) 977-9900 (phone_number) — Registrant's telephone number
FAQ
What specific items are included in the 'Other Events' section of this 8-K filing?
The provided excerpt does not detail the specific events covered under 'Other Events'.
Does this 8-K filing disclose any new financial results for INSMED Inc. as of August 12, 2025?
The excerpt indicates the filing includes 'Financial Statements and Exhibits' but does not provide specific financial results within the text.
What is the primary purpose of this 8-K filing for INSMED Inc. on August 12, 2025?
The filing serves as a Current Report under Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
Where are INSMED Inc.'s principal executive offices located?
INSMED Inc.'s principal executive offices are located at 700 US Highway 202/206, Bridgewater, New Jersey 08807.
What is the SEC file number for INSMED Inc.?
The SEC file number for INSMED Inc. is 000-30739.
Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 10.1 · Accepted 2025-08-12 11:55:42
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share INSM Nasdaq Global Select
Filing Documents
- ef20053490_8k.htm (8-K) — 32KB
- ef20053490_ex99-1.htm (EX-99.1) — 34KB
- ef20053490_ex99-2.htm (EX-99.2) — 18KB
- ef20053490_ex99-2slide2.jpg (GRAPHIC) — 242KB
- ef20053490_ex99-2slide3.jpg (GRAPHIC) — 140KB
- ef20053490_ex99-2slide4.jpg (GRAPHIC) — 141KB
- ef20053490_ex99-2slide5.jpg (GRAPHIC) — 142KB
- ef20053490_ex99-2slide7.jpg (GRAPHIC) — 143KB
- ef20053490_ex99-2slide10.jpg (GRAPHIC) — 203KB
- ef20053490_ex99-2slide14.jpg (GRAPHIC) — 117KB
- ef20053490_ex99-2slide17.jpg (GRAPHIC) — 169KB
- ef20053490_ex99-2slide19.jpg (GRAPHIC) — 160KB
- ef20053490_ex99-2slide20.jpg (GRAPHIC) — 134KB
- ef20053490_ex99-2slide22.jpg (GRAPHIC) — 89KB
- image001.jpg (GRAPHIC) — 7KB
- 0001140361-25-030537.txt ( ) — 2551KB
- insm-20250812.xsd (EX-101.SCH) — 4KB
- insm-20250812_lab.xml (EX-101.LAB) — 21KB
- insm-20250812_pre.xml (EX-101.PRE) — 16KB
- ef20053490_8k_htm.xml (XML) — 4KB
01 —
ITEM 7.01 — Regulation FD Disclosure. On August 12 , 2025, Insmed Incorporated (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has approved BRINSUPRI (brensocatib 25 mg and 10 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis in adults and children 12 years and older. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The Company will host a conference call to discuss the FDA approval on August 12 , 2025, at 12:00 p.m., Eastern Time, and a live webcast of the call will be available through the investor relations section of the Company's website. A copy of the slide presentation to be used by the Company during the conference call is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. The information contained in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 —
ITEM 8.01 — Other Events. On August 12 , 2025, the Company announced that the FDA has approved BRINSUPRI (brensocatib 10 mg and 25 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis in adults and children 12 years and older.
01 —
ITEM 9.01 —
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Insmed Incorporated on August 12, 2025. 99.2 Insmed Incorporated August 12, 2025 BRINSUPRI FDA Approval Presentation. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 12, 2025 INSMED INCORPORATED By: /s/ Michael A. Smith Name: Michael A. Smith Title: Chief Legal Officer and Corporate Secretary